{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:44:54Z","timestamp":1775688294066,"version":"3.50.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.rmed.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T22:31:19Z","timestamp":1492468279000},"page":"28-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators"],"prefix":"10.1016","volume":"128","author":[{"given":"David M.","family":"Halpin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-7201","authenticated-orcid":false,"given":"Richard K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.04.008_bib1","unstructured":"Forum of International Respiratory Societies. Realities of today - opportunities for tomorrow. Available at: http:\/\/www.theunion.org\/what-we-do\/publications\/technical\/english\/FIRS_report_for_web.pdf (Accessed 10 May 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib2","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD). Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs315\/en\/(Accessed 10 May 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib3","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD). Available at: http:\/\/www.who.int\/respiratory\/copd\/burden\/en\/(Accessed 10 May 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib4","unstructured":"World Health Organization. Asthma. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs307\/en (Accessed 18 Febraury 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib5","series-title":"Global Initiative for Asthma (GINA)","author":"Global Strategy for Asthma Management and Prevention","year":"2016"},{"key":"10.1016\/j.rmed.2017.04.008_bib6","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Available at: http:\/\/www.goldcopd.org\/(Accessed 23 March 2016)."},{"issue":"13","key":"10.1016\/j.rmed.2017.04.008_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4155\/fmc.11.127","article-title":"Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease","volume":"3","author":"Busch-Petersen","year":"2011","journal-title":"Future. Med. Chem."},{"key":"10.1016\/j.rmed.2017.04.008_bib8","unstructured":"Boehringer Ingelheim. Asthma: new indication for Spiriva\u00ae (tiotropium) Respimat\u00ae* in the EU may offer millions of adults a significant advance in asthma care. Available at: https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2014\/08_september_2014_asthma.html (Accessed 1 January 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib9","unstructured":"Health Canada. Regulatory decision summary: Spiriva Respimat. Available at: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/rds-sdr\/drug-med\/rds_sdr_spiriva_respimat_175084-eng.php (Accessed 12 July 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib10","unstructured":"Boehringer Ingelheim. Asthma: U.S. FDA approves new indication for Spiriva\u00ae Respimat\u00ae. Available at: https:\/\/www.boehringer-ingelheim.com\/press-release\/asthma-us-fda-approves-new-indication-spiriva-respimat (Accessed 17 March 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/COPD.S76520","article-title":"Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease","volume":"10","author":"Jones","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/17476348.2015.996133","article-title":"Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease","volume":"9","author":"Riario-Sforza","year":"2015","journal-title":"Expert. Rev. Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40265-015-0532-5","article-title":"Inhaled umeclidinium in COPD patients: a review and meta-analysis","volume":"76","author":"Pleasants","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11208620-000000000-00000","article-title":"Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2017.04.008_bib15","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"7","author":"Karner","year":"2014","journal-title":"Cochrane. Database. Syst. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1378\/chest.14-1698","article-title":"What is the role of tiotropium in asthma?: a systematic review with meta-analysis","volume":"147","author":"Rodrigo","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.04.008_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.02.012","article-title":"Effect of tiotropium on COPD exacerbations: a systematic review","volume":"114","author":"Halpin","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/COPD.S92412","article-title":"Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis","volume":"10","author":"Ismaila","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2017.04.008_bib19","doi-asserted-by":"crossref","first-page":"e009183","DOI":"10.1136\/bmjopen-2015-009183","article-title":"Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis","volume":"5","author":"Tricco","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2017.04.008_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/COPD.S71913","article-title":"Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease","volume":"10","author":"Miravitlles","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","article-title":"Muscarinic receptor antagonists: effects on pulmonary function","volume":"208","author":"Buels","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/17425250902828337","article-title":"Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients","volume":"5","author":"Price","year":"2009","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2040622313518227","article-title":"Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases","volume":"5","author":"Alagha","year":"2014","journal-title":"Ther. Adv. Chronic. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.rmed.2017.04.008_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2015.02.007","article-title":"Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD","volume":"31","author":"Cazzola","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2017.04.008_bib26","unstructured":"Boehringer Ingelheim Limited. Spiriva 18 microgram inhalation powder, hard capsule. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/10039\/SPC\/Spiriva+18+microgram+inhalation+powder%2c+hard+capsule\/(Accessed 1 February 2015)."},{"key":"10.1016\/j.rmed.2017.04.008_bib27","unstructured":"Boehringer Ingelheim Limited. Spiriva Respimat 2.5 microgram inhalation solution. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/20134\/SPC (Accessed 1 January 2015)."},{"key":"10.1016\/j.rmed.2017.04.008_bib28","unstructured":"AstraZeneca UK Limited. Eklira Genuair 322 micrograms inhalation powder. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/27001 (Accessed 10 May 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib29","unstructured":"Novartis Pharmaceuticals UK Ltd. Seebri Breezhaler inhalation powder, hard capsules 44mcg. Available at:https:\/\/www.medicines.org.uk\/emc\/medicine\/27138\/(Accessed 10 May 2016)."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.rmed.2017.04.008_bib31","unstructured":"GlaxoSmithKline UK. Incruse 55 micrograms inhalation powder, pre-dispensed. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/29394 (Accessed 7 June 2016)."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2332\/allergolint.09-RAI-0106","article-title":"Differences of inflammatory mechanisms in asthma and COPD","volume":"58","author":"Ichinose","year":"2009","journal-title":"Allergol. Int."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1183\/09031936.00004907","article-title":"Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison","volume":"30","author":"Bos","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2017.04.008_bib34","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.rmed.2007.06.009","article-title":"Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in\u00a0vitro","volume":"101","author":"Buhling","year":"2007","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pupt.2010.03.008","article-title":"Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD","volume":"23","author":"Wollin","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-016-0327-6","article-title":"Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a Guinea pig model of chronic asthma","volume":"17","author":"Kistemaker","year":"2016","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/jpet.116.232009","article-title":"Tiotropium attenuates virus-induced pulmonary inflammation in cigarette smoke-exposed mice","volume":"357","author":"Bucher","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.rmed.2017.04.008_bib38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00146610","article-title":"Tiotropium inhibits pulmonary inflammation and remodelling in a Guinea pig model of COPD","volume":"38","author":"Pera","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2012.05.007","article-title":"Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects","volume":"66","author":"Santus","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.rmed.2017.04.008_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.pupt.2009.06.002","article-title":"Alternative mechanisms for tiotropium","volume":"22","author":"Bateman","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/09031936.00023907","article-title":"Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD","volume":"30","author":"Powrie","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2016.04.001","article-title":"Downregulation of the cough reflex by aclidinium and tiotropium in awake and anesthetized rabbits","volume":"38","author":"Mutolo","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2017.04.008_bib43","first-page":"1829","article-title":"The relationship between cough-specific quality of life and abdominal muscle endurance, fatigue, and depression in patients with COPD","volume":"10","author":"Arikan","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib44","series-title":"Data on File","author":"Boehringer Ingelheim","year":"2016"},{"issue":"15","key":"10.1016\/j.rmed.2017.04.008_bib45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s40265-014-0307-4","article-title":"Tiotropium Respimat\u00ae Soft Mist\u2122 inhaler: a review of its use in chronic obstructive pulmonary disease","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1183\/09031936.00127809","article-title":"Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial","volume":"36","author":"Troosters","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib47","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/npjpcrm.2015.67","article-title":"Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial","volume":"25","author":"Wise","year":"2015","journal-title":"NPJ. Prim. Care Respir. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12931-015-0216-4","article-title":"Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT\u00ae trial","volume":"16","author":"Tashkin","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib49","series-title":"Safety of Tiotropium in Patients with Cardiac Events in the TIOSPIR\u00ae Trial","author":"Wise","year":"2015"},{"issue":"16","key":"10.1016\/j.rmed.2017.04.008_bib50","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rmed.2008.10.002","article-title":"The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients","volume":"103","author":"van Noord","year":"2009","journal-title":"Respir. Med."},{"issue":"15","key":"10.1016\/j.rmed.2017.04.008_bib52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A\u00a04-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9696","key":"10.1016\/j.rmed.2017.04.008_bib53","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.15326\/jcopdf.2.3.2014.0142","article-title":"Effect of tiotropium on outcomes in patients with COPD, categorized using the new GOLD grading system: results of the UPLIFT randomized controlled trial","volume":"2","author":"Halpin","year":"2015","journal-title":"J.\u00a0COPD F."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.00082909","article-title":"Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial","volume":"35","author":"Tashkin","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A\u00a06-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2017.04.008_bib57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib58","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2017.04.008_bib60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A\u00a0blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study","volume":"14","author":"Chapman","year":"2014","journal-title":"BMC. Pulm. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/COPD.S102494","article-title":"A\u00a0randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 \u03bcg compared with tiotropium 18 \u03bcg in patients with COPD","volume":"11","author":"Feldman","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2466-13-54","article-title":"Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey","volume":"13","author":"Barnes","year":"2013","journal-title":"BMC. Pulm. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.rmed.2006.07.010","article-title":"Patient's perception of exacerbations of COPD\u2013the PERCEIVE study","volume":"101","author":"Miravitlles","year":"2007","journal-title":"Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2017.04.008_bib64","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1741-7015-11-181","article-title":"Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease","volume":"11","author":"Wedzicha","year":"2013","journal-title":"BMC. Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15326\/jcopdf.2.2.2014.0155","article-title":"Effects of tiotropium on exacerbations in patients with COPD with low or high risk of exacerbations: a post-hoc analysis from the 4-Year UPLIFT\u00ae trial","volume":"2","author":"Celli","year":"2015","journal-title":"J.\u00a0COPD F."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.09-0011","article-title":"Cardiovascular safety of tiotropium in patients with COPD","volume":"137","author":"Celli","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2017.04.008_bib69","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.201508-1647OC","article-title":"Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial","volume":"193","author":"Stone","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib70","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000089655","article-title":"The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease","volume":"73","author":"Verkindre","year":"2006","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.rmed.2017.04.008_bib71","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O'Donnell","year":"2004","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib72","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2147\/COPD.S91684","article-title":"Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial","volume":"10","author":"Santus","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.resp.2014.03.012","article-title":"Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients","volume":"197","author":"Santus","year":"2014","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"12","key":"10.1016\/j.rmed.2017.04.008_bib74","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rmed.2012.09.015","article-title":"Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients","volume":"107","author":"Vogelmeier","year":"2013","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib78","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1185\/03007995.2013.858618","article-title":"Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies","volume":"30","author":"D'Urzo","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.rmed.2017.04.008_bib79","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1753465814565624","article-title":"Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression","volume":"9","author":"Oba","year":"2015","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00011-2015","article-title":"Prevention of COPD exacerbations: medications and other controversies","volume":"1","author":"Vestbo","year":"2015","journal-title":"ERJ Open Res."},{"issue":"11","key":"10.1016\/j.rmed.2017.04.008_bib82","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib84","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.09-2992","article-title":"Reported pneumonia in patients with COPD: findings from the INSPIRE study","volume":"139","author":"Calverley","year":"2011","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.rmed.2017.04.008_bib85","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"23","key":"10.1016\/j.rmed.2017.04.008_bib86","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib87","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2040622315609251","article-title":"Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease","volume":"7","author":"George","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib89","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib90","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"suppl 59","key":"10.1016\/j.rmed.2017.04.008_bib91","article-title":"Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels","volume":"46","author":"Calverley","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.rmed.2017.04.008_bib92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann. Intern Med."},{"issue":"121","key":"10.1016\/j.rmed.2017.04.008_bib93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1183\/09059180.00004311","article-title":"Night-time symptoms: a forgotten dimension of COPD","volume":"20","author":"Agusti","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2017.04.008_bib94","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-4-31","article-title":"Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study","volume":"4","author":"Carrasco","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4104\/pcrj.2010.00067","article-title":"Effect of tiotropium on quality of life in COPD: a systematic review","volume":"19","author":"Kaplan","year":"2010","journal-title":"Prim. Care Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12931-014-0122-1","article-title":"Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study","volume":"15","author":"Miravitlles","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/COPD.S48570","article-title":"Impact of night-time symptoms in COPD: a real-world study in five European countries","volume":"8","author":"Price","year":"2013","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib98","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1465-9921-14-112","article-title":"COPD symptoms in the morning: impact, evaluation and management","volume":"14","author":"Roche","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2147\/COPD.S76157","article-title":"Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease","volume":"10","author":"Stephenson","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2017.04.008_bib100","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium+olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib101","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S48967","article-title":"Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis","volume":"8","author":"Karabis","year":"2013","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib102","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1378\/chest.127.3.809","article-title":"Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD","volume":"127","author":"Casaburi","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib103","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.128.3.1168","article-title":"Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD","volume":"128","author":"Maltais","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib104","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1378\/chest.12-2613","article-title":"Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial","volume":"144","author":"Cooper","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.04.008_bib105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","article-title":"Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial","volume":"7","author":"Beeh","year":"2012","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib106","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2466-14-209","article-title":"Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial","volume":"14","author":"Beeh","year":"2014","journal-title":"BMC. Pulm. Med."},{"issue":"6","key":"10.1016\/j.rmed.2017.04.008_bib107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1753465814559209","article-title":"Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials","volume":"8","author":"Maltais","year":"2014","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib108","doi-asserted-by":"crossref","first-page":"14009","DOI":"10.1038\/npjpcrm.2014.9","article-title":"Asthma control and management in 8,000 European patients: the REcognise asthma and LInk to symptoms and experience (REALISE) survey","volume":"24","author":"Price","year":"2014","journal-title":"NPJ. Prim. Care Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib109","first-page":"84","article-title":"Anticholinergics for treatment of asthma","volume":"25","author":"Quirce","year":"2015","journal-title":"J.\u00a0Investig. Allergol. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2011.06.004","article-title":"Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg\/Arg patients with asthma","volume":"128","author":"Bateman","year":"2011","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2017.04.008_bib111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-15-61","article-title":"Tiotropium Respimat\u00ae in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma","volume":"15","author":"Beeh","year":"2014","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib112","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/jamp.2015.1260","article-title":"Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium respimat in asthma using standardized sample-contamination avoidance","volume":"29","author":"Beeh","year":"2016","journal-title":"J.\u00a0Aerosol. Med. Pulm. Drug Deliv."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib113","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaci.2016.01.011","article-title":"Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial","volume":"138","author":"Hamelmann","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib114","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaci.2011.04.039","article-title":"Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial","volume":"128","author":"Kerstjens","year":"2011","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"13","key":"10.1016\/j.rmed.2017.04.008_bib115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib116","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","article-title":"Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials","volume":"3","author":"Kerstjens","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib117","doi-asserted-by":"crossref","first-page":"e0124109","DOI":"10.1371\/journal.pone.0124109","article-title":"Long-term once-daily tiotropium Respimat\u00ae is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study","volume":"10","author":"Ohta","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rmed.2017.04.008_bib118","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaip.2015.08.017","article-title":"The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial","volume":"4","author":"Paggiaro","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib119","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.rmed.2014.12.005","article-title":"Once-daily tiotropium Respimat\u00ae 5 mug is an efficacious 24-h bronchodilator in adults with symptomatic asthma","volume":"109","author":"Timmer","year":"2015","journal-title":"Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2017.04.008_bib120","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.rmed.2014.06.011","article-title":"Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study","volume":"108","author":"Vogelberg","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib121","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12931-015-0290-7","article-title":"Erratum to: a randomised dose-ranging study of tiotropium Respimat\u00ae in children with symptomatic asthma despite inhaled corticosteroids","volume":"16","author":"Vogelberg","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib122","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12931-015-0175-9","article-title":"A\u00a0randomised dose-ranging study of tiotropium Respimat\u00ae in children with symptomatic asthma despite inhaled corticosteroids","volume":"16","author":"Vogelberg","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib123","first-page":"11","article-title":"Tiotropium in asthma: a systematic review","volume":"7","author":"Befekadu","year":"2014","journal-title":"J.\u00a0Asthma Allergy"},{"issue":"12","key":"10.1016\/j.rmed.2017.04.008_bib124","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.5588\/ijtld.14.0275","article-title":"Long-acting anticholinergic agents in patients with uncontrolled asthma: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"5","key":"10.1016\/j.rmed.2017.04.008_bib125","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4187\/respcare.02703","article-title":"Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis","volume":"59","author":"Tian","year":"2014","journal-title":"Respir. Care"},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib126","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40258-014-0107-8","article-title":"Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists","volume":"12","author":"Willson","year":"2014","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.rmed.2017.04.008_bib127","first-page":"1","article-title":"Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide","volume":"8","author":"Price","year":"2015","journal-title":"J.\u00a0Asthma Allergy"},{"key":"10.1016\/j.rmed.2017.04.008_bib128","first-page":"453","article-title":"Comparing Respimat\u00ae Soft Mist\u2122 inhaler and DPI aerosol deposition by combined in\u00a0vitro measurements and CFD simulations","volume":"2","author":"Ciciliani","year":"2014","journal-title":"Respir. Drug Deliv."},{"issue":"2","key":"10.1016\/j.rmed.2017.04.008_bib129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.rmed.2009.11.011","article-title":"Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients","volume":"104","author":"Ichinose","year":"2010","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib130","first-page":"559","article-title":"A\u00a0dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients","volume":"2","author":"Caillaud","year":"2007","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib131","unstructured":"Actavis UK Ltd. Ipratropium bromide 250 micrograms\/1ml and 500 micrograms\/2ml nebuliser solution (breath limited). Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/27927 (Accessed 10 May 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib132","first-page":"239","article-title":"Tiotropium HandiHaler\u00ae and Respimat\u00ae in COPD: a pooled safety analysis","volume":"10","author":"Halpin","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib133","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4187\/respcare.00852","article-title":"Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes","volume":"56","author":"Yohannes","year":"2011","journal-title":"Respir. Care"},{"issue":"10","key":"10.1016\/j.rmed.2017.04.008_bib134","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200906-0876OC","article-title":"Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease","volume":"180","author":"Celli","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials","volume":"342","author":"Singh","year":"2011","journal-title":"BMJ"},{"issue":"Suppl 58","key":"10.1016\/j.rmed.2017.04.008_bib136","first-page":"923","article-title":"Safety of tiotropium in renally impaired patients","volume":"44","author":"Tashkin","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib137","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.rmed.2016.07.001","article-title":"Safety and tolerability of once-daily tiotropium Respimat\u00ae as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis","volume":"118","author":"Dahl","year":"2016","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib138","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","article-title":"Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs","volume":"105","author":"Toy","year":"2011","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2017.04.008_bib139","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.rmed.2005.10.008","article-title":"Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide\/formoterol on the degree of resting pulmonary hyperinflation","volume":"100","author":"Santus","year":"2006","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/089426801316970268","article-title":"Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity","volume":"14","author":"Chodosh","year":"2001","journal-title":"J.\u00a0Aerosol. Med."},{"issue":"3","key":"10.1016\/j.rmed.2017.04.008_bib141","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jam.2005.18.273","article-title":"Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers","volume":"18","author":"Hochrainer","year":"2005","journal-title":"J.\u00a0Aerosol. Med."},{"key":"10.1016\/j.rmed.2017.04.008_bib142","first-page":"145","article-title":"Development of Respimat\u00ae Soft mist inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby","year":"2011","journal-title":"Med. Devices (Auckl.)"},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib143","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000363771","article-title":"The importance of continuity in inhaler device choice for asthma and chronic obstructive pulmonary disease","volume":"88","author":"Bjermer","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2017.04.008_bib144","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/COPD.S3391","article-title":"Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler","volume":"4","author":"Hodder","year":"2009","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S3452","article-title":"Asthma patients prefer respimat Soft mist inhaler to turbuhaler","volume":"4","author":"Hodder","year":"2009","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib146","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/COPD.S91118","article-title":"A\u00a0cross-sectional study to assess inhalation device handling and patient satisfaction in COPD","volume":"11","author":"Miravitlles","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2017.04.008_bib147","doi-asserted-by":"crossref","first-page":"e009015","DOI":"10.1136\/bmjopen-2015-009015","article-title":"Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial","volume":"5","author":"Dahl","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2017.04.008_bib148","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","article-title":"Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2017.04.008_bib149","unstructured":"Boehringer Ingelheim. New advance in COPD maintenance treatment, Spiolto\u00ae Respimat\u00ae, approved in first European countries. Available at: https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2015\/02_july_2015_copd.html (Accessed 1 January 2016)."},{"key":"10.1016\/j.rmed.2017.04.008_bib150","first-page":"A4445","article-title":"Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models","volume":"181","author":"Bouyssou","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 55","key":"10.1016\/j.rmed.2017.04.008_bib151","article-title":"Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized Guinea pigs","volume":"38","author":"Bouyssou","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2017.04.008_bib152","first-page":"1179","article-title":"Profile of a fixed-dose combination of tiotropium\/olodaterol and its potential in the treatment of COPD","volume":"10","author":"Muruganandan","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.04.008_bib153","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/TCRM.S84151","article-title":"Pharmacologic rationale underlying the therapeutic effects of tiotropium\/olodaterol in COPD","volume":"11","author":"Pelaia","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.rmed.2017.04.008_bib154","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2147\/COPD.S88246","article-title":"Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease","volume":"10","author":"Ramadan","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2017.04.008_bib155","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2017.04.008_bib156","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","article-title":"Efficacy of tiotropium+olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis","volume":"32","author":"Ferguson","year":"2015","journal-title":"Adv. Ther."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117301221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117301221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:36:22Z","timestamp":1760614582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117301221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":156,"alternative-id":["S0954611117301221"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.04.008","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}